S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:IMVT

Immunovant - IMVT Stock Forecast, Price & News

$18.29
+0.09 (+0.49%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.70
▼
$18.50
50-Day Range
$12.70
▼
$19.72
52-Week Range
$3.14
▼
$20.24
Volume
1.03 million shs
Average Volume
1.31 million shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

Immunovant MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
7.8% Downside
$16.86 Price Target
Short Interest
Healthy
4.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Immunovant in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.35 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.56) to ($1.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

Medical Sector

963rd out of 1,030 stocks

Biological Products, Except Diagnostic Industry

158th out of 169 stocks

See Top Rated MarketRank™ Stocks Here
IMVT stock logo

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Stock News Headlines

January 28, 2023 | americanbankingnews.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Mark S. Levine Sells 10,156 Shares
December 29, 2022 | finance.yahoo.com
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 16, 2022 | finance.yahoo.com
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
December 15, 2022 | finance.yahoo.com
Are Medical Stocks Lagging Immunovant (IMVT) This Year?
November 8, 2022 | finance.yahoo.com
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
November 7, 2022 | finance.yahoo.com
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
November 4, 2022 | finance.yahoo.com
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
February 3, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
October 20, 2022 | finance.yahoo.com
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab
October 9, 2022 | finance.yahoo.com
While institutions invested in Immunovant, Inc. (NASDAQ:IMVT) benefited from last week's 63% gain, public companies stood to gain the most
October 7, 2022 | nasdaq.com
These Biotech Stocks Hit New 52-week High, Were They In Your Portfolio? - Nasdaq
October 6, 2022 | nasdaq.com
Health Care Sector Update for 10/04/2022: GBS, IMVT, KALV - Nasdaq
October 6, 2022 | fool.com
Why Immunovant Stock Is Skyrocketing This Week - The Motley Fool
October 6, 2022 | finance.yahoo.com
Why Immunovant Stock Is Skyrocketing This Week
October 6, 2022 | uk.investing.com
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday By Benzinga - Investing.com UK
October 5, 2022 | benzinga.com
Why Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Da - Benzinga
October 5, 2022 | streetinsider.com
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing - StreetInsider.com
October 5, 2022 | uk.investing.com
RPM International, Lamb Weston And Some Other Big Stocks Moving Higher On Wednesday By Benzinga - Investing.com UK
October 5, 2022 | marketwatch.com
Immunovant Shares Rise 32% After $75M Stock Offering Prices - MarketWatch
October 5, 2022 | benzinga.com
Nasdaq Surges 250 Points; Crude Oil Rises Sharply - FaZe Holdings (NASDAQ:FAZE), AeroClean Technologies ( - Benzinga
October 5, 2022 | finance.yahoo.com
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner - Yahoo Finance
October 4, 2022 | benzinga.com
Nasdaq Surges 350 Points; Crude Oil Rises Sharply - FaZe Holdings (NASDAQ:FAZE), AeroClean Technologies ( - Benzinga
October 4, 2022 | benzinga.com
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner - Benzinga
October 4, 2022 | benzinga.com
Immunovant shares are trading lower after the company announced pricing of a $75 million underwritten offering of common stock. - Immunovant (NASDAQ:IMVT) - Benzinga
October 4, 2022 | seekingalpha.com
Inhibrx, Immunovant top healthcare gainers; Biohaven, KalVista lead losers' pack - Seeking Alpha
October 4, 2022 | globenewswire.com
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock - GlobeNewswire
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Company Calendar

Last Earnings
11/05/2021
Today
2/03/2023
Next Earnings (Estimated)
2/03/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
CUSIP
N/A
CIK
1764013
Web
www.immunovant.com
Phone
N/A
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.86
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
-7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-156,730,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.15%
Return on Assets
-36.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.41
Quick Ratio
13.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
4.53

Miscellaneous

Outstanding Shares
129,180,000
Free Float
125,307,000
Market Cap
$2.36 billion
Optionable
Not Optionable
Beta
1.00

Key Executives

  • Dr. Frank M. Torti M.B.A. (Age 44)
    M.D., MBA, Exec. Chairperson of the Board
    Comp: $94.11k
  • Dr. Peter Salzmann M.B.A.Dr. Peter Salzmann M.B.A. (Age 55)
    M.D., CEO & Director
    Comp: $979.96k
  • Ms. Eva Renee Barnett M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $534.98k
  • Dr. William L. Macias M.D.Dr. William L. Macias M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $4.85M
  • Dr. Julia G. Butchko Ph.D. (Age 52)
    Chief Devel. & Technology Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations
  • Mr. Mark S. Levine (Age 50)
    Chief Legal Officer & Corp. Sec.
  • Ms. Lauren Schrier M.B.A.
    VP of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IMVT Stock - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings or view top-rated stocks.

What is Immunovant's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price objectives for Immunovant's stock. Their IMVT share price forecasts range from $5.00 to $30.00. On average, they anticipate the company's share price to reach $16.86 in the next twelve months. This suggests that the stock has a possible downside of 7.8%.
View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 at the beginning of the year. Since then, IMVT stock has increased by 3.0% and is now trading at $18.29.
View the best growth stocks for 2023 here.

Are investors shorting Immunovant?

Immunovant saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,430,000 shares, a decline of 32.5% from the December 31st total of 3,600,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 2.1 days. Approximately 4.7% of the shares of the company are sold short.
View Immunovant's Short Interest.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our IMVT earnings forecast.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings results on Friday, November, 4th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41).

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.20%), Sigma Planning Corp (0.04%), Strs Ohio (0.03%), Concorde Asset Management LLC (0.01%), ProShare Advisors LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $18.29.

How much money does Immunovant make?

Immunovant (NASDAQ:IMVT) has a market capitalization of $2.36 billion. The company earns $-156,730,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via email at info@immunovant.com.

This page (NASDAQ:IMVT) was last updated on 2/3/2023 by MarketBeat.com Staff